Publication:
Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis.

cris.virtual.author-orcid0000-0002-3830-8508
cris.virtualsource.author-orcidade91a16-6e2b-4d1c-b538-15aac7c36747
dc.contributor.authorFurukawa, Toshi A
dc.contributor.authorSalanti, Georgia
dc.contributor.authorAtkinson, Lauren Z
dc.contributor.authorLeucht, Stefan
dc.contributor.authorRuhe, Henricus G
dc.contributor.authorTurner, Erick H
dc.contributor.authorChaimani, Anna
dc.contributor.authorOgawa, Yusuke
dc.contributor.authorTakeshima, Nozomi
dc.contributor.authorHayasaka, Yu
dc.contributor.authorImai, Hissei
dc.contributor.authorShinohara, Kiyomi
dc.contributor.authorSuganuma, Aya
dc.contributor.authorWatanabe, Norio
dc.contributor.authorStockton, Sarah
dc.contributor.authorGeddes, John R
dc.contributor.authorCipriani, Andrea
dc.date.accessioned2024-10-24T17:52:20Z
dc.date.available2024-10-24T17:52:20Z
dc.date.issued2016-07-08
dc.description.abstractINTRODUCTION Many antidepressants are indicated for the treatment of major depression. Two network meta-analyses have provided the most comprehensive assessments to date, accounting for both direct and indirect comparisons; however, these reported conflicting interpretation of results. Here, we present a protocol for a systematic review and network meta-analysis aimed at updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression. METHODS AND ANALYSIS We will include all randomised controlled trials reported as double-blind and comparing one active drug with another or with placebo in the acute phase treatment of major depression in adults. We are interested in comparing the following active agents: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. The main outcomes will be the proportion of patients who responded to or dropped out of the allocated treatment. Published and unpublished studies will be sought through relevant database searches, trial registries and websites; all reference selection and data extraction will be conducted by at least two independent reviewers. We will conduct a random effects network meta-analysis to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. To rank the various treatments for each outcome, we will use the surface under the cumulative ranking curve and the mean ranks. We will employ local as well as global methods to evaluate consistency. We will fit our model in a Bayesian framework using OpenBUGS, and produce results and various checks in Stata and R. We will also assess the quality of evidence contributing to network estimates of the main outcomes with the GRADE framework. ETHICS AND DISSEMINATION This review does not require ethical approval. PROSPERO REGISTRATION NUMBER CRD42012002291.
dc.description.numberOfPages4
dc.description.sponsorshipInstitut für Sozial- und Präventivmedizin (ISPM)
dc.identifier.doi10.7892/boris.86093
dc.identifier.pmid27401359
dc.identifier.publisherDOI10.1136/bmjopen-2015-010919
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/143863
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.relation.ispartofBMJ open
dc.relation.issn2044-6055
dc.relation.organizationDCD5A442BECFE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BDB9E17DE0405C82790C4DE2
dc.subjectAntidepressants
dc.subjectMajor depression
dc.subjectNetwork meta-analysis
dc.subjectSystematic review
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.titleComparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.issue7
oaire.citation.startPagee010919
oaire.citation.volume6
oairecerif.author.affiliationInstitut für Sozial- und Präventivmedizin (ISPM)
oairecerif.author.affiliation2Berner Institut für Hausarztmedizin (BIHAM)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.description.ispublishedpub
unibe.eprints.legacyId86093
unibe.journal.abbrevTitleBMJ Open
unibe.refereedTRUE
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Furukawa BMJOpen 2016_e010919.pdf
Size:
1.99 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by-nc/4.0
Content:
published

Collections